REGENXBIO Inc.
corporate_fare Company Profile
REGENXBIO Inc. (NASDAQ:RGNX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 34 items for RGNX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-23, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 18 rated 8 or above. Recent SEC coverage for RGNX spans 8-K, 10-Q, 424B5, FWP.
Recent high-impact activity:
- REGENXBIO Settles ELEVIDYS Patent Litigation, Secures $39M Payment from Sarepta
- FDA Clinical Hold on RGX-121; BLA Resubmission Not Expected Near Term
- FDA Clinical Hold on RGX-121 Sends Regenxbio Down 22%
- Regenxbio Swings to Q2 Profit on $100M AbbVie Milestone, Extends Cash Runway to Q4 2027
- REGENXBIO Reports Q2 Profit Driven by $100M Milestone, Extends Cash Runway into Q4 2027
Financial Snapshot
Short Interest & Short Volume
7.66 days to coverFINRA reported short interest of 7,927,603 shares in RGNX as of the September 15, 2026 settlement, a 5.7% increase from the prior period — about 7.7 days to cover at its recent average daily volume. On October 2, 2026, 49.9% of RGNX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for RGNX, detected from its recent SEC filings · based on capital-structure filings through 2026-07-20.
$100M Offering Priced at Deep Discount · Net Proceeds of ~$94M Extend Runway
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →